PremiumCompany AnnouncementsAcurx Pharmaceuticals’ Optimistic Earnings Call Highlights Clinical Progress Acurx price target lowered to $5 from $14 at Alliance Global Partners Acurx reports Q4 EPS (16c) vs. (37c) last year PremiumThe FlyAcurx files to sell 2.61M shares of common stock for holders Acurx to sell 2.46M shares at $1.015 in registered direct offering Acurx receives positive EMA guidance for ibezapolstat Phase 3 program PremiumThe FlyAcurx reports Q3 EPS (17c) vs. (24c) last year Acurx’s ibezapostat shows favorable effect in Phase 2b CDI trial Acurx’s ibezapolstat shows positive results in CDI and Anthrax 
